CAMBRIDGE, Mass., Feb. 1, 2023
/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a
biopharmaceutical company with the purpose to better the lives of
people impacted by kidney disease, granted three newly-hired
employees options to purchase an aggregate of 18,000 shares of
Akebia's common stock on January 31,
2023, as inducements material to such employee entering into
employment with Akebia. The options were granted in accordance with
Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $0.63 per share, which is equal to the closing
price of Akebia's common stock on the grant date. The stock options
vest over four years, with 25% of the shares vesting on the first
anniversary of the grant date and the remaining 75% of shares
vesting quarterly thereafter, in each case, subject to the new
employee's continued service with Akebia. Each stock option has a
10-year term and is subject to the terms and conditions of Akebia's
inducement award program and a stock option agreement covering the
grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is
a fully integrated biopharmaceutical company with the purpose to
better the lives of people impacted by kidney disease. Akebia was
founded in 2007 and is headquartered in Cambridge, Massachusetts. For more
information, please visit our website at www.akebia.com, which
does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301736390.html
SOURCE Akebia Therapeutics